Summary
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients with a high interferon gene signature, a subgroup it plans to emphasize in future development discussions with regulators.
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.
Alumis Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 410 | $1,636.31 | $11,119.2 | $9,482.89 | 579.53% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 23 | $567.79 | $583.51 | $15.72 | 2.77% |
| NA Nizar Araji National Bank Of Canada /FI/ | 25 | $703.5 | $690 | -$13.5 | -1.92% |
| BG Bart Gancher Intech Investment Management LLC | 20,853 | $106,956.96 | $575,542.8 | $468,585.84 | 438.11% |
| NSS Neil S. Shapiro Towerview LLC | 222,294 | $1.81M | $6.03M | $4.22M | 233.85% |
Alumis Inc. (ALMS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alumis Inc. ever had a stock split?
Alumis Inc. Profile
| Biotechnology Industry | Healthcare Sector | Martin Babler CEO | NASDAQ (NGS) Exchange | 022307102 CUSIP |
| US Country | 237 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alumis Inc. is a clinical-stage biopharmaceutical entity dedicated to forging new paths in the treatment of autoimmune disorders. This commitment is underpinned by its focus on the research, development, and eventual commercialization of innovative medicinal solutions aimed at addressing a variety of autoimmune diseases. Marking a significant milestone in its journey, the company transitioned to Alumis Inc. in January 2022, evolving from its former identity as Esker Therapeutics, Inc. This rebranding reflects a broader strategic vision as it progresses with its clinical endeavors. Established in 2021, Alumis Inc. anchors its operations in South San Francisco, California, positioning itself in the vibrant hub of biotechnological innovation.
Products and Services
Within its innovative portfolio, Alumis Inc. is advancing the development of specialized therapeutic solutions, primarily focusing on:
- ESK-001: This prime candidate emerges as an allosteric tyrosine kinase 2 (TYK2) inhibitor, meticulously designed to combat a trio of conditions—plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. ESK-001 represents a novel approach in the immunological modulation of these diverse yet impactful autoimmune disorders, highlighting Alumis Inc.’s commitment to addressing complex medical needs through scientific ingenuity.
- A-005: Tailored for the profound challenges of neuroinflammatory and neurodegenerative diseases, A-005 leverages its distinction as a central nervous system-penetrant allosteric TYK2 inhibitor. This strategic focus on neurology underscores a deep reconnaissance into unlocking new therapeutic avenues for conditions traditionally constrained by limited treatment options, illuminating Alumis Inc.'s pioneering spirit in neuroscientific exploration.
